It will use the funds to help expand the development and commercialization of its non-invasive genetic tests for early-stage cancer detection.
Illumina Ventures was the sole investor in the Series A1 round, which will go toward Cernostics' clinical and market development studies for its TissueCypher Barrett's Esophagus assay.
The company intends to use the funds to support the commercial growth of its targeted sequencing assays.
The firm provides clinical genomic tests in India and has a research-focused NGS lab in California.
The financing will be used by the company to bring its breath-based diagnostic technology to market, fund clinical trials, and grow its precision medicine services.
Randox is using the funding, which includes £23 million from Invest NI, to create three centers in Northern Ireland to develop new diagnostic technologies.
The firm said it is close to completing development of a platform that aims to meet a need for cost-effective monitoring in countries with a high disease burden.
Genetic Technologies and Blockchain Global may partner to develop medical and biotechnology applications that combine their respective technologies.
The financing will support the company as it works to expand its diagnostic products for non-invasive early detection and monitoring of cancers.
Private equity firm Quadria Capital led the investment round and was joined by HealthQuad Fund and Heritas Venture Fund.